Skip to Content
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 06/19/17

Information below provided by the Pharmaceutical Company.

AZD8186

Agent Description

AZD8186 is a phosphatidylinositol 3-kinase (PI3K) beta/delta inhibitor being developed as an oral anti-tumor agent, with an initial focus on patients with phosphatase and tensin homolog (PTEN)-deficient disease.

Mechanism of Action

PI3K inhibition

Classification

PI3K inhibitor

Molecular Targets

PI3K beta/delta

Monograph

The PI3K/AKT/mTOR signaling network is a critical regulator of many cellular processes, including; normal cell proliferation, survival, and growth. Increased cellular activity of PI3 kinases, either through functional loss of the PTEN tumor suppressor protein (PI3 kinase antagonist) or PI3 kinase activation mutations, is associated with development of many tumor types and hematological malignancies. Two PI3 kinase isoforms, PI3K beta and PI3K delta, have been clinically validated as targets in a variety of cancers and malignancies.

Studies of Interest

Areas of interest:

AZD8186 is being investigated in advanced solid tumors. Proposals will be prioritized accordingly based on scientific merit and fit with the core development program. Additional preclinical work to support clinical settings of interest may be required.

Information collaborator would like included in investigator proposals

N/A